

## Technology Appraisal Committee B Interests Register

**Topic:** trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]

**Publication Date:** Tbc.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Peter Wheatly Price	TAC B Committee Member	Direct	<p>Takeda manufacture fruquintinib which is currently in process for Fruquintinib for previously treated metastatic colorectal cancer ID6274. The scope is People with metastatic colorectal cancer (mCRC) who have had two or more previous treatments.</p> <p>Whilst the comparators are not directly the same, I believe that the populations have significant overlap and that this then represents a commercial conflict of interest and I believe that this is too close or could be perceived as too close for me to participate</p>	19/04/2024	It was agreed that Peter's declaration would prevent him from participating in discussions on this appraisal.
David McAllister	TAC B Committee Member	Non-Financial Professional &	Work with data provided by sponsors or their competitors	28/05/2024	It was agreed that David's declaration would not prevent him from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
		Personal Interests	accessed via the Vivli trial data sharing platform.		participating in discussions on this appraisal.
Professor Mark Saunders	Clinical expert	Direct - Financial	<p>Over the last 3 years Mark has received payment from Servier for lectures, meetings and to attend international meetings. Since April 2020, he has had 12 such meetings receiving £15,000.</p> <p>He received a fee for a talk for BAYER at UK Oncology Forum in June 23 (£1912.50).</p>	15/05/2024	It was agreed that Professor Saunders' declaration would not prevent him from providing expert advice to the committee.
Professor Harpreet Wasan	Clinical expert		<p>Over the last 20 years, Harpreet has been on advisory boards and has done educational development work and invited talks on colorectal cancer for many organisations including drugs recently approved in Colorectal cancer by NICE:</p> <p>Regorafenib (BAYER)</p> <p>Trifluridine-tipiracil (SERVIER)</p>	15/05/2024	It was agreed that Professor Wasan's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Encorafenib, Binimetinib and Cetuximab in BRAFV600E CRC (Array then Pfizer)</p> <p>In the last 12 months:</p> <p>Bayer (regorafenib). YES advisory board compensated</p> <p>Merck Serono (cetuximab). YES research- project development uncompensated</p> <p>Pierre Fabre (encorafenib). YES CRC manuscript in development uncompensated</p> <p>Pfizer (bevacizumab, irinotecan) YES encorafenib- Breakwater Global trial on steering committee / UK CI</p>		